Table 2

Median survival time of patients with hepatocellular carcinoma

Parameter n Median survival (95% confidence interval) Log rank test
Overall2458.0  (6.4–11.9)
Female588 (6.1–12.0)p=0.6289
Male1878.6 (5.9–15.3)
Underlying cirrhosis2126.8 (5.5–9.9)p=0.0024
No liver cirrhosis3321.3 (13.9–62.5)
Child-Pugh stage
 A8412.0 (9.4–17.3)p=0.0001
 B936.8 (4.5–11.4)
 C351.9 (1.5–3.0)
Aetiology
 Chronic alcoholism866.8 (5.1–11.4)p=0.1309
 Hepatitis B243.4 (2.8–6.0)
 Hepatitis C9011.0 (6.7–15.3)
 Haemochromatosis1018.7 (16.0–*)
Edmondson-Steiner
 G14013.3 (6.1–17.3)p=0.0666
 G28311.1 (7.5–20.9)
 G3444.7 (2.8–11.0)
Okuda
 Stage 14015.8 (12.7–37.3)p=0.0001
 Stage 216110.2 (7.5–13.9)
 Stage 3442.7 (2.0–4.3)
TNM classification
 Stage 36412.8 (7.6–25.3)p=0.0028
 Stage 41525.8 (4.3–7.2)
VISUM classification
 Stage 113115.2 (12.4–27.1)p=0.0001
 Stage 2637.2 (4.4–12.7)
 Stage 3512.6 (2.0–3.4)
Age distribution
 <30237.3
 30–4045.6
 40–50238.6
 50–607211.0
 60–709210.4
 70–80485.3
 >80429.2
AFP distribution
 0–74513.9 (10.7–27.1)p=0.0179
 7–203410.2 (6.1–22.3)
 20–1003611.9 (4.6–17.0)
 100–500408.4 (4.2–15.3)
 >500815.4 (3.7–8.0)
PVT
 Yes564.0 (2.8–6.0)p=0.0007
 No1629.6 (7.9–15.3)
  • PTV, portal vein thrombosis; AFP, α fetoprotein.